A Phase I trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-VEGFR Inhibitor, in Children with Recurrent or Refractory Primary CNS Tumors

BACKGROUND: Cediranib (AZD2171), an oral, pan VEGF inhibitor, was evaluated in this phase I study to determine its toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics, in children and adolescents with recurrent or refractory primary...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Childs Nerv Syst
Main Authors: Kieran, Mark W., Chi, Susan, Goldman, Stewart, Onar-Thomas, Arzu, Poussaint, Tina Young, Vajapeyam, Sridhar, Fahey, Frederic, Wu, Shengjie, Turner, David C., Stewart, Clinton F., Moses, Marsha, Packer, Roger J., Jakacki, Regina, Banerjee, Anu, Boyett, James M., Fouladi, Maryam, Kun, Larry
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561207/
https://ncbi.nlm.nih.gov/pubmed/26188774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00381-015-2812-5
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker